FY2025 Earnings Forecast for SPRB Issued By Leerink Partnrs

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Spruce Biosciences in a report released on Monday, November 10th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($2.82) per share for the year, up from their prior estimate of ($2.96). The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for Spruce Biosciences’ Q4 2025 earnings at ($6.52) EPS, Q1 2026 earnings at ($6.72) EPS, Q2 2026 earnings at ($6.94) EPS, Q3 2026 earnings at ($7.16) EPS, Q4 2026 earnings at ($7.36) EPS, FY2026 earnings at ($28.18) EPS and FY2027 earnings at ($42.51) EPS.

Several other research analysts also recently weighed in on SPRB. JMP Securities set a $259.00 price target on Spruce Biosciences in a research note on Tuesday. Zacks Research downgraded Spruce Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Spruce Biosciences in a research note on Tuesday. Citizens Jmp increased their price objective on Spruce Biosciences from $254.00 to $259.00 and gave the company a “market outperform” rating in a research report on Tuesday. Finally, Citigroup reiterated a “market perform” rating on shares of Spruce Biosciences in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Spruce Biosciences currently has an average rating of “Hold” and an average target price of $178.88.

Spruce Biosciences Price Performance

NASDAQ SPRB opened at $102.19 on Thursday. The stock has a market capitalization of $51.10 million, a price-to-earnings ratio of -1.20 and a beta of 3.28. Spruce Biosciences has a one year low of $4.28 and a one year high of $240.00. The business’s fifty day moving average is $79.99 and its 200-day moving average is $32.10.

Spruce Biosciences (NASDAQ:SPRB) last issued its quarterly earnings data on Monday, November 10th. The company reported ($14.58) EPS for the quarter, topping analysts’ consensus estimates of ($15.56) by $0.98.

Institutional Investors Weigh In On Spruce Biosciences

A hedge fund recently bought a new stake in Spruce Biosciences stock. Carlyle Group Inc. acquired a new stake in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 2,896,518 shares of the company’s stock, valued at approximately $24,765,000. Spruce Biosciences accounts for about 0.6% of Carlyle Group Inc.’s portfolio, making the stock its 4th largest holding. Carlyle Group Inc. owned about 579.30% of Spruce Biosciences as of its most recent filing with the SEC. 91.71% of the stock is currently owned by institutional investors.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.